Fig. 3From: Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)a Boxplot showing median and IQR of BVAS/WG scores at entry, 6 months and 12 moths. b Boxplot showing of oral prednisolone dose (in mg) at baseline, 6 months and 12 monthsBack to article page